– IRELAND, Dublin – Prothena Corporation plc (NASDAQ: PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced the appointment of Dan Welch to its Board as an Independent Director and Chair Designate, to succeed Dr. Lars Ekman as Chair.
Additionally, Dr. Anders Harfstrand is not standing for re-election at the Annual Meeting.
“Dan is a highly respected business leader with a wealth of industry expertise, chair experience and a strong passion and proven ability for bringing innovative therapies to patients. He will help guide the company during this transformational time as it continues to advance a robust pipeline in neurodegenerative and rare peripheral amyloid diseases. We look forward to working closely with Dan on a seamless transition enabled by a shared commitment to develop and commercialize novel and transformative medicines to create a better future for people in critical need of new treatment options,” said Board Chair, Dr. Lars Ekman.
About Daniel G. Welch
Dan Welch serves as the chair of the boards of Structure Therapeutics Inc., Nuvation Bio Inc., and Ultragenyx Pharmaceuticals Inc. He recently served as a director of Seagen Inc. which was acquired by Pfizer in December 2023. He previously served as chair of the board of AveXis Inc. and as a director of Intercept Pharmaceuticals, Inc. and Hyperion Therapeutics.
Before these roles, he served as an executive partner at Sofinnova Ventures, as CEO and president of InterMune, Inc., as chair of the board of InterMune, as chair of the board and CEO of Triangle Pharmaceuticals, Inc., and as president of the pharmaceutical division of Elan Corporation, PLC.
“Prothena’s deep scientific expertise in protein dysregulation is reflected in its promising pipeline which is guided by patient-focused drug development. I am excited to join at a dynamic time for the company with multiple upcoming milestones that could establish Prothena as a leader in Alzheimer’s therapeutic approaches and rare peripheral amyloid diseases,” said Dan Welch. “I look forward to working with my fellow board members and the entire team at Prothena to further realize our vision to bring transformative therapies to those patients most in need.”
Mr. Welch earned his B.A. from the University of Miami and his M.B.A. from the University of North Carolina.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases.
SOURCE: https://www.prothena.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
